Quantified Bone Scan Response After Radium-223

ASCO 2014 - A Randomized, Open-Label Phase 2a Study Evaluating Quantified Bone Scan Response Following Treatment with Radium-223 Dichloride Alone or in Combination with Abiraterone Acetate or Enzalutamide in Patients with Castration-Resistant Prostate Cancer who have Bone Metastases

Daniel Petrylak, MD discusses a study designed to explore the utility of bone scan imaging to assess treatment response to radium-223.

Daniel Petrylak, MD
Yale Cancer Center

Click HERE to view the poster from this session

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe